Levels of neurotransmitter amino acids in the cerebrospinal fluid of patients with acute ischemic insult

被引：22

作者：

Skvortsova V.I. ^{[1
]}

Raevskii K.S. ^{[1
]}

Kovalenko A.V. ^{[1
]}

Kudrin V.S. ^{[1
]}

Malikova L.A. ^{[1
]}

Sokolov M.A. ^{[1
]}

Alekseev A.A. ^{[1
]}

Gusev E.I. ^{[1
]}

机构：

[1] Russian State Medical University, Science Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow

来源：

Neuroscience and Behavioral Physiology | 2000年 / 30卷 / 5期

关键词：

Glutamate; Severe Illness; Ischemic Insult; Glutamate Level; Gaba Level;

D O I：

10.1007/BF02462604

中图分类号：

学科分类号：

摘要：

The dynamics of excitatory (glutamate, aspartate) and inhibitory (GABA, glycine) neurotransmitter amino acid contents in the cerebrospinal fluid were studied in 110 patients with hemispheric ischemic insult. These studies revealed significant increases in the levels of glutamate and aspartate in the first six hours of illness, and the level and duration of these changes correlated with the severity of the insult. Peak GABA and glycine levels were seen at the end of the first day after strokes, reflecting the delayed activation of the mechanisms of protective inhibition. The insufficiency of GABAergic mediation in strokes located in the hemispheres to a significant extent mirrored the severity of clinical featues and the potential of restorative processes. Early significant biochemical criteria were identified for objective assessment of the severity of brain ischemia, and these had prognostic value for the course and outcome of strokes. The most unfavorable prognostic signs were the presence of low (or undetectable) GABA levels in the first days after insult and progressive increases in aspartate levels to the third day on the background of sharp reductions in glutamate levels (after initial elevation on the first day).

引用

页码：491 / 495

页数：4

共 18 条

[1]

Gusev E.I., Skvortsova V.I., Map for the Investigation and Treatment of Patients with Ischemic Insult, (1990)

[2]

Gusev E.I., Skvortsova V.I., Raevskii K.S., Et al., Basic Studies as the Foundation for Creating Therapeutic Substances, pp. 133-134, (1995)

[3]

Gusev E.I., Skvortsova V.I., Kovalenko A.V., Sokolov M.A., Zh. Nevrol. Psikhiatr., 2, pp. 71-76, (1999)

[4]

Gusev E.I., Skvortsova V.I., Komissarova I.A., Et al., Zh. Nevrol. Psikhiatr., 2, pp. 18-26, (1999)

[5]

Erecinska M., Nelson D., Wilson D.R., Et al., Brain Res., 304, pp. 19-23, (1984)

[6]

Ferrarese C., Pecora N., Frigo M., Et al., Ann. Neurol, 33, 3, pp. 316-319, (1993)

[7]

Ginsberg M.D., Cerebrovascular and Brain Metabolism Reviews, 2, pp. 68-93, (1990)

[8]

Ginsberg M.D., New Strategies to Prevent Neural Damage from Ischemia, pp. 1-32, (1994)

[9]

Globus M.Y.-T., Rusto R., Martiner E., Et al., J. Neurochem., 57, pp. 470-478, (1991)

[10]

Gusev E.I., Skvortsova V.I., Burd G.S., Et al., J. Neurol. Sci., 150, pp. 81-82, (1997)

← 1 2 →